Figure 5.
Evaluation of in vivo DC activation after IV and IM injection of mRNA LNPs. (A-B) C57BL/6J mice were treated with free mBCMA mRNA or mRNA LNPs with or without poly(I:C) LNPs by either the IV or IM route. After 24 hours of treatment, the spleens were isolated and splenocytes were analyzed for DC activation markers CD80 or CD40 on CD11c+ DCs. (C-E) Immunofluorescence analysis of the spleen showing activation of CD11c (yellow) and CD80 (magenta) after 24-hour treatment with different groups. The scatter plots represent percentage of CD80+ DCs after IV and IM injections of different treatment groups. The data are shown as mean ± SD from at least 3 independent biological experiments. Statistical analysis was performed using an unpaired Student t test: ∗P < .05. DAPI, 4′,6-diamidino-2-phenylindole.

Evaluation of in vivo DC activation after IV and IM injection of mRNA LNPs. (A-B) C57BL/6J mice were treated with free mBCMA mRNA or mRNA LNPs with or without poly(I:C) LNPs by either the IV or IM route. After 24 hours of treatment, the spleens were isolated and splenocytes were analyzed for DC activation markers CD80 or CD40 on CD11c+ DCs. (C-E) Immunofluorescence analysis of the spleen showing activation of CD11c (yellow) and CD80 (magenta) after 24-hour treatment with different groups. The scatter plots represent percentage of CD80+ DCs after IV and IM injections of different treatment groups. The data are shown as mean ± SD from at least 3 independent biological experiments. Statistical analysis was performed using an unpaired Student t test: ∗P < .05. DAPI, 4′,6-diamidino-2-phenylindole.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal